Out of those methods, FISH is the gold standard in detecting ALK rearrangement in NSCLC due to its detection of rearrangements regardless of what the variant and fusion partner, use of archival formalin-fixed paraffin embedded tissue, low tumor cell requirement (~100 tumor cells), clinical validation, and its FDA approval for clinical applications [2]. The gene discussed is ALK; the disease is neoplasm.